1. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS. (June 2017) Authors: Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M.J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P.L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Morschhauser, F.; Tilly, H.; Chaidos, A.; Phillips, T.; Ribrag, V.; Campbell, P.; Ghandi Laurent, D.; Jurczak, W.; McKay, P.; Opat, S.; Radford, J.; Rajarethinam, A.; Yang, J.; Howell, H.; Newberry, K.J.; Adib, D.; Salles, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗